ESMO26: Wider use of breast cancer gene test could save NHS £4m annually

Veracyte’s Prosigna is used to determine which breast cancer patients can be safely treated without the need for chemotherapy. Veracyte’s Prosigna is used to determine which breast cancer patients can be safely treated without the need for chemotherapy. This year’s edition of ESMO took place from 23 to 27 October in Madrid, Spain. Credit: sasirin pamai/Shutterstock.com A genomic test to support treatment decision-making for women with early breast cancer could save the UK National Health Service (NHS) up to £4m ($5.3m) annually if used more widely, according to new research led by University College London (UCL). The research was presented…

Source: Medical Device Network